1. Home
  2. LDP vs PHAR Comparison

LDP vs PHAR Comparison

Compare LDP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Limited Duration Preferred and Income Fund Inc.

LDP

Cohen & Steers Limited Duration Preferred and Income Fund Inc.

N/A

Current Price

$19.60

Market Cap

615.9M

Sector

Finance

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$10.44

Market Cap

793.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LDP
PHAR
Founded
2012
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
615.9M
793.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LDP
PHAR
Price
$19.60
$10.44
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$38.33
AVG Volume (30 Days)
69.6K
15.9K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$19.35
$9.62
52 Week High
$22.05
$21.34

Technical Indicators

Market Signals
Indicator
LDP
PHAR
Relative Strength Index (RSI) 19.99 38.38
Support Level $19.35 $9.62
Resistance Level $20.93 $13.51
Average True Range (ATR) 0.18 0.40
MACD -0.10 -0.05
Stochastic Oscillator 4.51 5.87

Price Performance

Historical Comparison
LDP
PHAR

About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.

Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: